7th Inflammasome Therapeutics Summit

Unlocking the Potential of Targeting the Innate Immune System

After years of rigorous research and foundational progress, the inflammasome drug development field is reaching a critical inflection point. With long-awaited clinical data now beginning to emerge, momentum is building, and the landscape is evolving rapidly. NodThera has shared encouraging results in Parkinson’s disease and obesity, Ventus has initiated a Phase IIa clinical trial, and Ventyx is progressing a diversified pipeline of inflammasome-targeting assets. As the race for first-in-class success accelerates, the field stands on the cusp of transformative breakthroughs.

Now in its 7th year, the Inflammasome Therapeutics Summit remains the only industry event dedicated exclusively to inflammasome-targeted drug development. Bringing together over 70 leading drug developers, translational scientists, and clinical experts, this summit offers a unique platform to exchange insights, benchmark clinical progress, and shape the next chapter of therapeutic innovation.

Across neuroinflammation, metabolic disorders, and autoimmune diseases, this meeting will explore the most current clinical data, emerging strategies, and scientific advances. Join your peers to hear directly from those driving programs forward, tackle the most pressing translational challenges, and help chart the future of inflammasome therapeutics.



URLs:
Website: https://go.evvnt.com/3153719-0?pid=2874
Brochure: https://go.evvnt.com/3153719-2?pid=2874


Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development

Prices:
Full Package - Drug Developer Pricing - On the Door: USD 4197.00,
Conference Only - Drug Developer Pricing - On the Door: USD 2999.00,
Full Package - Academic Pricing - On the Door: USD 3597.00,
Conference Only - Academic Pricing - On the Door: USD 2599.00,
Full Package - Solution Provider Pricing - On the Door: USD 5097.00,
Conference Only - Solution Provider Pricing - On the Door: USD 3699.00

Speakers: Alan Watt President and Chief Scientific Officer NodThera Ltd., Brian Levy Chief Executive Officer InflammX Therapeutics, Cynthia Lebeaupin Senior Scientist Pfizer, DENISA WAGNER PROFESSOR, SENIOR INVESTIGATOR Harvard Medical School, Elad Elkayam Principal Investigator Ventus Therapeutics, Elliott Gruskin Chief Executive Officer Azome Therapeutics, Hal Hoffman Professor, Pediatrics University of California, San Diego, John Nuss Chief Scientific Officer Ventyx Biosciences, Juan Pablo de Rivero Vaccari Associate Professor University of Miami School of Medicine, Kathleen Ogilvie SVP Translational and Non-Clinical Research Ventyx Biosciences, Kiran Bhaskar Scientific Co-Founder TheraVac Biologics, Lauren Martens Vice President - Biology Neumora Therapeutics, Inc., Marc Pelletier Associate Director, Translational Immune Oncology Novartis AG, Olaf Groß Chief Scientific Officer University Medical Center Freiburg, Paul Ashton Chief Executive Officer Inflammasome Therapeutics, Rashmin Savani Head, Scientific Advisory Board Azome Therapeutics, Roberto De Luca Instructor in Neurology Beth Israel Deaconess Medical Center (Harvard Medical School), Roberto Negro Senior Scientist IRCCS, Shawn Seong CEO Shaperon, Stephen Glover Chief Executive Officer ZyVersa Therapeutics